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INTRODUCTION FOR ANNUAL REPORT 1993
New programs, new people, new projects the story of the Cancer Committee
in 1 993 at St. Luke’s Medical Center. In addition, other activities were guided
-

in part by the following priority goals for the year. The goals were chosen by
the committee and overseen through the year by one physician and one
program staff member. Efforts were begun in all areas, however reportable
accomplishments will not be achieved until next year.
Cancer Committee Goals for 1993-1994
. Monitor and react to health care reform as it relates
to cancer service
. Collaborate with other hospital programs including Women’s
and Men’s Health
. Develop strategies to involve primary care physicians in the
cancer program
. Develop a service management plan for all oncology departments
. Develop comprehensive, quality disease site programs in a
cost effective manner

Marcia J.S.
Richards, M.D.
A

Chairperson of
Cancer Committee

There were many programmatic highlights this year. The 1st Surgical
Oncology Conference was coordinated by the energetic surgical oncology
subcommittee featuring four internationally known speakers addressing
diverse topics. Radiology saw the opening of a new Breast Imaging Center,
including the use of stereotaxic needle biopsy in the new outpatient facility.
Under the guidance of the Rehabilitation Medicine Department, a program for
oncologic rehabilitation was initiated which was aimed at outpatients. For the
first time Tumor Conferences continued for the summer, with a new format of
co-moderators. Intense work was also begun on developing a coordinated
program for the care of patients with breast cancer with departmental standards developed by each involved department and/or section.
Ongoing quality assurance activities with the American College of Surgeons
included long and short term review studies of patients with cervical and
prostate cancer. Additionally, institutional studies were done evaluating the
oncology Beta-indicator study for the Joint Commission on Accreditation of
Healthcare Organizations (JCAHO), and a study looking at the correlation of
CT directed needle biopsies of the lung with open biopsies for patients with
undifferentiated malignancies.
Activities through the Vince Lombardi Cancer Clinic (and supported by the
generous efforts of the Lombardi Classic and Ball) included outreach lectures
on oncologic topics given by our staff and visiting speakers. Highlights
included “Survivorship Issues” discussed by Susan Leigh from the National
Coalition for Cancer Survivors and Susan Ford addressing her experience with
her mother’s breast cancer to a large audience at the Italian Community
Center. Other community efforts included co-sponsorship with the American
Cancer Society of the Bike-a-thon and a 24 Hour Relay. Lombardi efforts also
continued to support a number of institutional research projects.
Ann LeFever, Ph.D., was added as a research scientist in the immunotherapy

and bone marrow program and Marcia Marino started as the Cancer Center
chaplain. We also saw the departure of Nancy Nowak as Program Director to
warmer environs.
Another year well done by all members of the cancer committee and the entire
oncology program.
Marcia J.S. Richards, M.D.
Chair of Cancer Committee
1

SCREENNG MAMMOGRAPHY FOR PRE-MENOPAUSAL
WOMEN: A MEDICAL CONTROVERSY
According to the American Cancer Society, there will be 3,800 new cases of
breast cancer in the state of Wisconsin in 1994. Although most of these
patients will present with early stage disease, approximately 25 percent of
these patients will succumb to their breast disease.

William J. Pao,
MD

Among ‘the prognostic factors for breast cancer, early age at diagnosis
(usually less than or equal to age 35) and pre-menopausal status, has been
found to be an adverse prognostic factor. It is interesting when factored with
size, axillary lymph node status, and other biochemical factors, age looses its
significance. Nonetheless, younger women who develop breast cancer tend
to have worse disease. What makes it more significant is that many of these
patients, due to their age, have full time occupations and often have young
children at home. Their deaths pose a problem for care givers.
One of the significant factors in the advance for cancer detection has been
mammography. The technical aspects, equipment and expertise of
physicians interpreting the studies has significantly improved in the last 20
years. This is where the controversy begins.
Thus far, there have been more than 8 randomized studies in looking at the
efficacy of mammography improving survival. To discuss their findings in
detail is beyond the scope of this article but suffice to say, their scientific
conclusion thus far is as follows:
The first is that women 50 years of age or over definitely benefit from
screening mammography. There is a significant reduction in mortality from
breast cancer in women routinely screened compared to patients followed by
their physicians alone.
The second is that there is no specific survival advantage in the age
group 40-49.
There could be many reasons why that is so. But an obvious one is that the
greatest risk of a woman to developing breast cancer is her age. That is why
by screening older women, one can pick up more cancer cases and hence
make a difference in survival.
The National Cancer Institute therefore recommends screening mamm
ography to begin yearly at age 50 based on this scientific evidence thus far.
The American Cancer Society, however, still recommends yearly screening at
age 40-49. You may ask, “Why?”. This is because the data in the same
randomized studies also cannot disprove the hypothesis that screening is not
beneficial for younger patients. Being more of a patient advocacy group, the
American Cancer Society has decided not to change its recommendation for
the last 20 years.

2

What is a clinician to do? A good history and physical is important. In
patients with a strong family history of breast cancer, history of endometrial
cancer, etc., mammography may be needed at an earlier age. For most
patients, screening mammography is indicated after age 40. We still do not
have a national policy on breast cancer screening, but HMO or managed
care practice guidelines may later our practice behavior before long. Longer
follow-up of the randomized studies may also give us the answer to the
above questions.
William J. Pao, MD

1993

Breast Cancer

Age at Diagnosis

Age

According to the 1 993 National Cancer Data
Base, Breast Cancer is primarily a disease of
older patients, with approximately 75% of
patients being over the age offifty. In 1992,
3,442 patients were diagnosed with breast
cancer in Wisconsin, ofthese patients, 2,757
(20%) were 50 years ofage or older. St. Luke’s
Medical Center reports similar figures, in that
77% ofour patients were over fifty years of age
when diagnosed with breast cancer.
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( The 2 male cases were patients diagnosed
between the ages of 65-69 and have been
included in the above numbers)
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GENETIC AND ENVIRONMENTAl FACTORS PREDISPOSING
AND FOSTERING ThE DEVELOPMFNT OF BRFASI CANCER

B. Rafael Elejalde,
M.D., AFACOG,
FACOMG

“In the United States, no woman is at such low risk from breast cancer that
she can be excluded from education and screening programs appropriate for
her age. Even if no risk factors are present, one woman of every 1 1 develops
this disease”. Henney JE., deVita Jr. VT., Harrison’s Principles of Internal
Medicine. Several factors have been identified as increasing the risk of a
woman developing cancer of the breast, such as: family history, age, exposure
to radiation, migration from one country to live in another, ethnic ancestry
and exposure to diethylstilbestrol. The risk associated with family is higher
when the mother had bilateral tumors (before menopause), less when there is
an affected first degree relative with uni or bilateral tumors (post
menopausal), and for a woman who is nulliparous or had the first child after
30 and is SO years old. In 1990 Mary Clair King reported that S to 10% of
the cases of breast and ovarian cancer are due to the inheritance of a gene
(BRCA1 ) conferring predisposition to develop one r both tumors, when
other genetic changes specific to the target breast and ovarian cell take place.
This observation divides women into two groups with dramatically different
risks:

Cummulative Risk of Breast cancer
to Women in the United States
80-

a)

0)
Co

C
a)
0
a)

age
not inherited

—A— Inherited BRCA1

—

Adapted from King MC, Rowell S, Love S, JAMA 269: 1 975-80, 1 993

While the BRCA1 has not been isolated and characterized yet, its determina
tion by linkage at the present time and by direct mutation analysis when the
gene is identified, will allow for the precise risk assessment in families where
both, affected and non-affected women are available for analysis. Some will
have the mutated gene and will be at high risk, some will have the normal
gene and they will be at low risk. It is very likely that the gene will be isolated
in the near future. The recognition of the precise mutation will lead to exact
diagnosis of predisposition and hopefully to better preventive diagnosis and
care. St. Luke’s Medical Center and the Medical Genetics Institute will offer
integrated diagnosis and care in the near future.

B. Rafael Elejalde, M.D., AFACOG, FACOMG
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STEREOTACTIC BIOPSY
The National Cancer Institute estimates that 1 80,000 women are diagnosed
with cancer of the breast each year. Breast cancer will strike 1 in 8 women in
their lifetimes. While the statistics are alarming, data has shown that death
from breast cancer can be delayed or averted by early detection and treatment. High-quality x-ray mammography is clearly the single most important
factor in early detection. Unfortunately, a significant overlap exists in the
mammographic morphology of lesions, and the nonspecific signs of
malignancy frequently make benign conditions indistinguishable from
malignant processes. Only one in five biopsies performed for
mammographically-detected (nonpalpable) lesions is found to be malignant!
A nonsurgical technique has been developed that takes core biopsies of
mammographically suspicious areas. The procedure, called stereotactic core
biopsy, has been shown to be as accurate as traditional surgical biopsy
following needle localization.

Mark Wenzel, M.D.

Stereotactic core biopsy uses x-ray images and computer analysis to localize
the suspicious area in the breast. Initially, with the patient in the prone
position, the breast is placed through a round opening in the biopsy table.
( Please refer to Figure 1 ) With the breast in compression, stereo views of the
suspicious area are obtained. Using a workstation, the radiologist enters the
location of the lesion into the computer. Following skin preparation, local
anesthetic, and a small skin nick, a 14-gauge biopsy needle is passed into the
breast to a predetermined depth using the coordinates assigned by the
computer. Stereo views are obtained prior to and following biopsy to ensure
that the needle passes through the lesion. (Please refer to Figure 2) A minimum of six biopsies are performed depending on the adequacy of samples.
Advantages of stereotactic core biopsy over conventional needle localization
and surgical biopsy include: significantly decreased cost, elimination of the
potential for disfigurement, and decreased time required for arranging and
performing the biopsy. The technique has the potential to greatly reduce the
number of surgical biopsies for benign breast disease. Stereotactic core biopsy
will play an increasingly significant role in the diagnosis and management of
breast cancer.

Mark Wenzel, M.D.

i1

Figure 1

Figure 2
Stereotactic core biopsy images of46-year-old woman with a nonpalpa
ble 1 .4 cm spiculated mass discovered by mammography. Pathologic
analysis reveals poorly differentiated infiltrating duct cell carcinoma.
5

PAThOLOGIC FACTORS AND PROGNOSTIC INDICATORS
IN BREAST CARCINOMA
A variety of features have been evaluated as pathologic factors and prognostic
indicators for breast carcinoma. The most important factors that could
influence the management of breast carcinoma include: (A) morphologic
aspects, (B) steroid receptors, (C) immunohistochemical markers,
( D) tumor oncogenes, (E) proliferative rate, and (F) nuclear morphometry.
(A) Morphologic Features Some lesions that constitute a risk factor for the
subsequent development of invasive breast carcinoma include: intraductal
hyperplasia and scierosing adenosis (slight risk), atypical intraductal and
lobular hyperplasia (moderate risk), and intraductal carcinoma in-situ (high
risk). The relative risk doubles when there is a family history of breast cancer.
-

Jorge G. Pellegrini,
M.D.

Patients with tumors two centimeters in diameter or smaller (gross) have a
significantly better prognosis and survival than larg5r tumors. Medullary,
Tubular, Mucinous (Colloid), Adenoid Cystic Secretory, Cribriform and
Papillary carcinomas are low grade histologic cancer types associated with a
low frequency or absence of axillary node metastasis and a relatively good
prognosis. Poorly differentiated, Signet ring cell carcinomas, Inflammatory
carcinomas and Carcinosarcomas are generally considered aggressive
neoplasms. Stromal invasion is the most significant prognostic indicator since
non-invasive carcinomas are almost invariably cured by mastectomy. Tumor
grade is important in that high grade tumors have a higher frequency of
axillary node metastasis, tumor recurrences and death from metastatic
disease. The presence of 25% or more intraductal component is associated
with decreased nodal metastasis and a more favorable prognosis. The
prognostic significance of lymphoplasmacytic host response is controversial.
Lymphatic, blood vessel and perineural invasion are prognostically
unfavorable findings in node-negative patients treated by mastectomy.
Regarding axillary lymph nodes status, the ten year surgical failure for
patients is 86.5% with four or more positive nodes, 64.5% with one to three
positive nodes and 24% with no positive nodes. The presence of gross, rather
than microscopic metastasis in these nodes, adversely affects the prognosis.
The presence of metastatic tumor in internal mammary nodes, especially
when associated with axillary and supraclavicular nodes, portends an
ominous outlook. Unfavorable prognosis also include extranodal
tissue extension of tumor in patients with three or fewer involved nodes and
involvement of the axillary apical lymph nodes.
(B) Steroid Receptors Determination of estrogen receptors (ER) and
progesterone receptors (PR) in invasive breast carcinomas prior to therapeutic
manipulations has become standard practice. Tumors that are better differen
tiated are more likely to be ER positive and PR negativity has correlated well
with high grade tumors. Patients with ER and PR positive carcinomas have a
better overall survival than patients with only one negative receptor or
patients with ER and PR negative carcinomas. There is indication that PR
correlates better than ER with tumor recurrence regardless of lymph node
status and that PR negative patients have a shorter disease free interval than
PR positive patients.
-

(C) Immunohistochemical Markers BETA-i Glycoprotein (SP-i) positive
tumors have a higher frequency of axillary node metastases. Tumor cells
reactive to two specific Lectins (blood group isoantigens) have significantly
reduced recurrence-free and overall survival. Vimentin has been correlated
with tumor grade and has been significantly associated with a higher growth
rate as measured with the Ki-67 antibody.
-

(D) Oncogenes Insight into the genetic changes involved in the development
and progression of malignant neoplasms has been gained from the study of
oncogenes. Disease free survival is significantly reduced in C-erb B-2 (HER2/neu) positive patients with axillary metastases but not among those with
-
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negative nodes. Also, overall survival is significantly lower in C-erb B-2
positive patients regardless of nodal status. Patients with alter C-myc gene
expression and amplification of hst-1/int-2 have a significantly shorter
disease free and overall survival. High levels of Cathepsin D appear to be
associated with aggressive tumor behavior, shortened relapse-free and over all
survival in node-negative breast cancer patients but is not an independent
predictor of outcome because of its strong association with several
well-established prognostic indicators.
(E) Proliferative Rate The rate of DNA synthesis has been correlated with
prognosis and is determined by the thymidine labeling index (TLI),
Bromodeoxyuridine (BRdU) and recently by labeling index (3H-Tdr), for
example; high TLI has been associated with higher frequency of recurrence,
earlier recurrence and shorter survival after recurrence. P53 oversuppression
is an independent marker for shortened 6 year relapse-free and overall
survival in node negative patients with resectable breast cancer. Combined
ploidy and S-phase fraction (SPF) define two categories as favorable (diploid,
low SPF) and unfavorable (diploid, high SPF or any aneuploid subgroups).
Patients in the favorable category have a better five year post recurrence
survival rate and disease-free survival when compared to the unfavorable
category.
-

I

( F) Nuclear Morphometry Inverse relationships have been observed between
mean nuclear area, mean nuclear diameter, mitotic index, and prognosis.
-

Jorge G. Pellegrini, M.D.
10 Most Frequent Histologies For Breast Cancer in 1988
Histology
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SURGICAL OFIIONS FOR BREAST CANCER

Wendy M.
Mikkelson, M.D.

The two main options for the treatment of invasive breast cancer remain either
lumpectomy with axillary dissection and radiation therapy or modified radical
mastectomy. The cure rates are equal in Stage I and Stage II disease. This
means that even if lymph nodes are palpable preoperatively, the patient can
still be a candidate for breast conservation with equivalent results to those
obtained with modified radical mastectomy in terms of cure rates. Although
the American College of Surgeons has gone on record with the
recommendation to utilize breast conservation when possible because of its
equal cure rate, many women still undergo modified radical mastectomy. This
can be secondary to a woman’s preference or can occur because of a surgeon’s
recommendations. In Wisconsin, less than 20% of the women in the Medicare
population with the diagnosis of invasive breast cancer undergo breast
conservation procedures. It is interesting to speculate why this is the case.
Contraindications to breast conservation include: relatively large tumor size in
comparison to breast size, multifocal or multicentric breast carcinoma,
inflammatory breast carcinoma, and possibly invasive breast carcinoma with
an extensive intraductal component.
When modified radical mastectomy is performed, it can often be accompanied
by an immediate reonstruction technique such as an implant or expander
placement. Flap reconstruction can also be used. Immediate reconstruction
can be a viable option even if post operative chemotherapy is contemplated.
However, many plastic surgeons will recommend against immediate
reconstruction if post operative radiation is likely to be recommended.
Non-invasive breast cancer can be treated by wide excision alone, wide
excision with radiation therapy or with a total mastectomy. The NSABP study
Bi 7 showed that the local recurrence rate for patients who underwent
lumpectomy alone without radiation therapy was much higher than in those
who underwent the lumpectomy followed by radiation therapy. Seventy-two
women ( 1 8 % ) of those undergoing lumpectomy alone had a local recurrence
in the operated breast. Only thirty-two (8 %) of those undergoing lumpectomy
with radiation therapy had local recurrence. Because of these results, at this
time, lumpectomy with post operative radiation should be the standard of care
for non-invasive breast cancer for those who desire breast conservation. Total
mastectomy decreases the local recurrence rate even more, but does not
eliminate the chance of recurrence. Again, if a mastectomy is chosen,
immediate reconstruction is a reasonable option if the patient desires it.
One issue that needs to be resolved in the future is the utility of axillary
dissection. Lymphedema occurs in a small number of women, but its
morbidity is not negligible. At this time, axillary dissection is used in invasive
breast cancer to help with staging and give prognostic information. With
many women having node negative breast cancer often receiving recommenda
tions for chemotherapy, and as tumor markers and other prognostic indicators
become more accurate, it may well be that within the next decade or so the
utility of an axillary dissection will become much less and it will only be done
for therapeutic rather than prognostic or diagnostic reasons.

Wendy M. Mikkelson, M.D.
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EXERCISE POST MASTECTOMY
Following a mastectorny or lumpectomy with axillary dissection, exercise is
essential to regain full use of the involved arm and prevent loss of function
during daily activities. Immobilization of the arm after surgery can result in
tightness of the shoulder, abnormal posture and decreased strength. Early
initiation of a comprehensive exercise program including range of motion,
strengthening and good posture exercises help to assure return of full use of
the involved arm after surgery. Routine range of motion can also prevent
excessive swelling from developing in the arm or hand.
Good posture is essential in providing good alignment of the neck, back and
shoulder girdle to provide optimal function of the shoulder. Good posture
also helps prevent chest wall tightness from developing. Precautions to be
followed after surgery include: avoiding heavy lifting, carrying the purse on
the opposite shoulder, wearing watch or lewelry on unaffected arm, and
wearing loose fitting rubber glove on hand when washing dishes. Also, the
patient should avoid injections and blood pressures on the involved arm.
The patient’s physician will typically recommend when to start exercise
( usually 2-4 days after surgery). Exercise instructions may vary depending on
the physician or a nurse may also show the patient some exercises before
leaving the hospital. A volunteer from the American Cancer Society “Reach
to Recovery” program may visit the patient’s home and show them some
exercises. A Physical or Occupational therapist offers instructions in an
individualized exercise program for posture, range of motion, gentle
stretching and strengthening, as well as massage if needed to prevent
excessive scar tissue tightness. A physician’s referral is necessary for Physical
or Occupational Therapy.
Remember, daily exercise is essential post mastectomy for the patient to regain
full use of their arm. Good posture, a thorough exercise program and
following specific precautions can help speed up recovery.
Jackie Lamberton, P.T.

,
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RECONSTRUCTION/PLASTIC SURGERY FOR
BREAST CANCER
Rehabilitation of the breast cancer patient in the 90’s frequently involves
reconstruction following mastectomy. Many women find an external
prosthesis unsatisfactory for a variety of reasons. Though not a perfect
replacement, a reconstructed breast will allow the patient greater freedom of
clothing and activity. Numerous studies support the efficacy of breast
reconstruction following modified radical mastectomy. Patient satisfaction is
quite high, over 90% in most studies.
A review of patients treated at St. Luke’s Medical Center in 1928 and in 1993
have revealed certain trends. In 1988, a total of 15 patients underwent
reconstruction out of a total of 1 8 8 seen and treated for primary carcinoma of
the breast, for a total of 7.9%. In 1993, 19 patients or 7.6% of the total 248
women with breast cancer, underwent reconstruction. This probably reflects
two trends, one would be the smaller pool of patients available for reconstruc
tion because of the greater trend toward breast conèrvation. Out of this
smaller pool, however, more women do seem to be opting for reconstruction.

Paul W.
Loewenstein, MD

The basic techniques for reconstruction have been available for the last 10
years. Refinements and improvements, however, continue to take place.
Improvements in the surface characteristics of implants have generally led to
softer, more natural results with reconstruction. Both saline and gel filled
implants are currently available for the patient undergoing breast
reconstruction. Companies involved in the manufacture of implants are
working with material that is better tolerated by the patient and more
radiographically “friendly”.

Type of Reconstruction
198$
(19 Patients)

1993
(22 Patients)
0

59%
(13)

79 %

(15) Implant
or Tissue Expander

10

(9) Implant or
Tissue Expander

Another trend that is occurring is that toward using autologous tissue. In
1988, only 4 out of the 1 9 patients underwent TRAM (Transverse Rectus
Abdominous Musculocutaneous) flap reconstruction. The remaining 15 all
were reconstructed with implants with or without a first stage use of tissue
expander. In 1993, TRAM flaps outnumbered implant reconstruction by 13
to 9. Part of this no doubt is due to the negative publicity urrounding breast
implants. On the other hand, most studies support the conclusion that
reconstruction with the TRAM flap leads to a better cosmetic result.
Another trend observed is the increasing performance of breast reconstruction
at the time of the mastectomy. Many studies support the safety of this type of
a procedure. The benefit to the patient is now unquestioned. In 192$, ten of
the reconstructions were done immediately and 9 in a delayed fashion. In
1993, 1 2 reconstructions were done immediately and only 4 in a delayed
fashion.

A

Finally, the widespread use of the TRAM flap has led to the ability to salvage
the patient with chest wall recurrence following radiation. Several patients
have undergone extensive chest wall resections which can be reconstructed
using the TRAM flap.
In conclusion, we have seen that Milwaukee reflects national trends in the
treatment of breast cancer. Estimates of the numbers undergoing
reconstruction nationwide range from S to 20%. There are definite trends
toward the greater use of autologous tissue, primarily the TRAM flap, and
reconstruction being done at the time of the mastectomy.
Paul W. Loewenstein, MD

Timing of Reconstruction
1993
(22 Patients)

1988
(19 Patients)

I

47%

(9) Delayed
A
L:___________

18%
(4) Delayed

82%
(18)
(10) Immediate
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CANCER OF THE BREAST:
THE ROLE OF RADIATION ThERAPY
The use of ionizing radiation to treat patients with cancer of the breast started
within a few years of the discovery of X-rays by Wilhelm Roentgen in 1 895.
Early practitioners of radiation therapy benefited their patients by improving
the local control of breast cancer and relieving or decreasing their symptoms
produced by advanced disease. Modern radiotherapy rational and techniques
pursue ‘these same goals for patients, but with a better defined understanding
of how to more frequently achieve the desired patient outcomes with the least
treatment related acute and long term morbidity.

Marcia J.S.
Richards, M.D.

Additionally, new questions about the application of radiation therapy and/or
methods of delivery for breast cancer patients are being asked with the advent
of more limited surgical techniques, better screening methods which identify
earlier disease, and systemic treatments effective in preventing and/or delaying
distant relapse. Many issues posed by these changes in breast cancer and its
treatment are currently being addressed in clinical trials in which patients at
St. Luke’s may participate.
Post-operative radiation therapy for breast cancer is utilized to improve local
control. It is delivered following breast conserving surgery in patients with
early cancer, after mastectomy in patients with large primary tumors (>5 cm)
and/or with extensive regional node involvement (>4 nodes or 25% of axillary
lymph nodes involved). In both situations, randomized trials have
documented a reduction in the local recurrence rate from 20-40% without
post-operative radiation to 5-10% with post operative radiation at 5-10 year
follow-up. No definite benefit on survival is clearly apparent, but achieving
local control, considering the problems which may be associated with
uncontrolled local disease, adds significantly to the potential quality of an
individual’s life.
Palliative radiation therapy for breast cancer is utilized to relieve symptoms in
patients with advanced disease. Occasionally this may be aggressive local
treatment in patients with advanced disease. This is something which is
justified in such patients with cancer of the breast because of occasional long
term survival, even with locally advanced disease at diagnosis. Shorter
palliative courses, usually from 1-3 weeks are more commonly given to
patients with distant metastasis to alleviate symptoms such as bone pain,
neurologic problems from metastatic disease, or symptoms from visceral
obstruction. Improvement in life quality, as measured by symptom relief,
should be expected in 80% of the patients. This is usually achieved with a
small investment of time, competitive costs, and minimal volume resulting in
limited treatment side effects for the patient. When the patient’s symptoms
originate from limited areas of disease involvement, radiation treatment is
often preferable to systemic management alone because of the lack of whole
body side effects during treatment, the rapidity of response of symptomatol
ogy, and the local eradication of the disease process. In many cases the need
for continued systemic management of symptoms is significantly reduced or
eliminated.
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Current radiation research issues include efforts to decrease the late morbidity
of post-operative radiation through improved techniques in radiation
planning and efforts to limit both the treatment volumes and doses based on
patient parameters. Issues related to the timing of systemic therapy and
integration with radiation are also under investigation. Better methods for
patient selection of different local treatment options based on pathologic and
prognostic studies of the tumor are also being studied. The use of radiation
therapy in non-invasive breast cancer is under extensive evaluation, since
between 5-10% of the women diagnosed with breast cancer now present with
this histologic pattern.
In summary, radiation therapy’s major achievement is improvement in quality
of life for patients with cancer of the breast. For women with early disease,
breast conserving treatment is possible and often preferable, and for patients
with advanced disease local symptoms are usually relieved.

Marcia J.S. Richards, M.D.

1993 Breast Cancer
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The incidence of breast cancer has been rising dramatically in the United
States since 1 982, based on data collected by the Surveillance,
Epidemiology, and End Results (SEER) program ofthe National Cancer
Institute. Over this period of time, incidence rates for in situ and localized
invasive tumors have been said to increase, while rates for regional and
distant tumors have remained stable. According to the National Cancer
Data Base (NCDB), the percentage of in situ cancers increased between
1985 and 1988 but was essentially constant between 1988 and 1990.
Because in situ carcinoma is identified only by mammography, this data
suggests a plateau in the use ofmammographic screening. When
reviewing St. Luke’s data, we note an increase in the incidence of breast
cancer from 1 988 to 1 993 and little change in the percentage of regional
and distant stage patients from 1 988 to 1 993, but unlike the NCDB, we
note a decrease in the percentage ofpatients diagnosed with in situ
carcinoma.
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SYSTEMIC THERAPY FOR BREAST CANCER
Surgery and radiation are LOCAL treatments for breast cancer, while
chemotherapy and hormonal agents represent a SYSTEMIC approach.
Immunotherapy is also a systemic modality but is still experimental.
Treatment is either ADJUVANT or PALLIATIVE. In the former, all palpable
or gross disease has been surgically removed and only microscopic disease
remains. Adjuvant treatment therefore aims to cure the patient of her breast
cancer by preventing a relapse. In palliative treatment however, the breast
cancer is not curable and the aim of therapy is to control the disease, thereby
eliminating symptoms and prolonging life. When breast cancer has
metastasized outside of the breast, it is generally incurable.
Whatever the aim of therapy, the drugs used may be the same.
The most frequently used hormonal agents in breas; cancer are Tamoxifen, an
anti-estrogen, and Megace, a progesterone-like drug. These drugs bind to
proteins on the surface of breast cancer cells known as hormone receptors and
theoretically interfere with cell growth. Typically these drugs work slowly
and it may take weeks to see a response. Both are in pill form and are
relatively easy to tolerate. Tamoxifen may cause or aggravate “hot flashes” in
a third of women. Other side effects are very infrequent but potentially
serious, such as blood clots, uterine cancer, and effects on the retina. Megace
typically stimulates appetite, causes some fluid retention and may also cause
blood clots.
.

Used in the adjuvant setting, Tamoxifen is the hormonal drug of choice.
Following breast surgery (mastectomy or lumpectomy), a patient whose
cancer cells demonstrate estrogen and progesterone receptors is prescribed 20
mg/day of Tamoxifen, for 2 to S years. Other “good side effects” include
about a 40% decrease in the risk of a second breast cancer, a decrease in
myocardial infarction and protection from osteoporosis. In the palliative
setting, either hormonal agent is given for 8 to 12 weeks. If the patient
responds, it is continued indefinitely or until the breast cancer becomes
resistant to the drug. A patient who achieves a significant response to one
hormonal agent is very likely to have another response to a second
hormonal agent.
Breast cancer is fairly sensitive to chemotherapy. There are at least 15 drugs
commercially available that may be used. The most active are Doxorubicin
( Adriamycin) and Taxol. Chemotherapy works more quickly than hormonal
agents and responses are more dramatic. In the adjuvant setting,
chemotherapy is favored over hormones when the patient is younger
( pre-menopausal), when the cancer lacks hormone receptors and when the
risk of relapse is very high (e.g. many axillary lymph nodes with cancer).
Usually combinations of 3 drugs are used, such as “CMF”
(cyclophosphamide, methotrexate and 5-flourouracil). These are given in
various schedules once or twice a month for at least 6 cycles. In recent years it
has been found that dose-intensity, or giving enough of these drugs to
substantially lower the white blood cell count, is as important as which drugs
are used. When going for a cure, it is important to try not to reduce
chemotherapy doses, and to deliver these on schedule. Autologous bone
marrow transplantation represents the greatest dose-intensity of
chemotherapy. It is still being studied and is currently reserved for patients
whose chance of relapse is virtually certain.
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Side effects common to most of these combinations include some nausea, hair
loss, low white cell count (and therefore increased risk of infection), mucositis
and fatigue. Adriamycin also has the additional toxicity of affecting the heart
muscle, usually after cumulative large doses.
Chemotherapy for metastatic breast cancer is used when the disease is hor
mone resistant, when there is life-threatening visceral disease (e.g. liver metas
tasis), and in the younger patient. Therapy is continued until the maximum
response is achieved or the cancer becomes resistant. Often, patients will
receive a combination of both chemotherapy and hormones, either all at once,
or in sequence.
In summary, chemotherapy and hormonal therapy for breast cancer treats the
entire patient. The treatment should be individualized to the patient and the
breast cancer. New drugs are needed to overcome resistant cancers and to
cross the blood-brain barrier.

Margery Strack, MD

SLMC 5-Year Survival Breast Cancer
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Comparison of Breast Cancer Survival Rates
for SLMC and SEER
Stage
All
Local
Regional
Distant

SLMC
76.4%
84.4%
60.7%
14.5%

SEER
78%
93%
71%
12%

SEER survival rates, per Cancer Facts & Figures 1993, are based on patients diagnosed between 198387, and followed through 1989. SLMC survival rates are based on 150 analytic breast cancer patients
diagnosed and/or treated in 1988 and followed through 1993.
-

According to 1 981 -1 987 SEER (Surveillance, Epidemiology and End
Results) data, printed within Cancer Facts & Figures 1 993: The S year
survival rate for localized breast cancer has risen from 78% in the 1940’s
to 93 % today. In situ (non-invasive) breast cancer survival approaches
1 00% If the cancer has spread regionally, however, the survival rate is
71 %, and for persons with distant metastases, the survival rate is 12%.
Survival rates for St. Luke’s patients diagnosed in 1 920 are displayed
above and are similar to those published by SEER.
-
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AJCC Stage at Diagnosis for Breast Cancer
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1993
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Stage I
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Percent
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93
91
17
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8
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36.7%
6.9%
6.0%
3.2%
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(64 Breast Cancer Cases from 1988
were not staged)

According to an article from Ca-A CancerJournal for Clinicians: Trials have showed comparable outcomes
for patients treated with CS + RT (conservative surgery + radiation therapy) and with mastectomy. At a
National Institutes ofHealth Consensus Development Conference on the treatment ofearly-stage breast
cancer in June 1 990, data on CS + RT and mastectomy was reviewed. Based on the results ofthe trials, the
panel concluded that breast conservation treatment is an appropriate method ofprimary therapy for the
majority ofwomen with Stage I and Stage II breast cancer, and is preferable because it provides survival
equivalent to total mastectomy and axillary dissection while preserving the breast. Histology, patient age,
tumor size, physical condition and ofcourse, patient preference must be considered when treatment is being
planned. The graphs above show that over 75% ofbreast cancer patients diagnosed or treated here at
St. Luke’s in 1 988 and in 1 993 were Stage I or II and m have been eligible for conservative surgery +
radiation therapy.
AJCC STAGE BY FIRST COURSE OF TREATMENT 1993 BREAST CANCER
-
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1
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VINCE LOMBARDI CANCER CLINIC UPDATE
The Vince Lombardi Cancer Clinic provides state of the art, comprehensive
care, to persons diagnosed with cancer. It is committed to the goal of
providing optimal medical and nursing care in an ambulatory setting.
Therefore, the clinic is open 7 days a week to meet the needs of the patient’s
home and work schedules. Our philosophy of care is patient/family centered.
Diagnostic and therapeutic interventions are available in the clinic to
maximize continuity of care (such as Chemotherapy, Immunotherapy,
Symptom mangement).
The Vince Lombardi Cancer Clinic supports the Autologous Bone Marrow
Reinfusion Program by providing apheresis services and pre and post
transplant care. To provide total support to women who have undergone
breast cancer surgery, members of the staff are certified breast form fitters.
Breast Forms and foundation garments are available to women as a service of
the clinic.

Marija Bjegovich,
RN

With the support of the Vince Lombardi Memorial Classic Funds, the Vince
Lombardi Cancer Clinic offers cancer prevention education (such as breast
self examination), early detection screenings, and funding for cancer-related
research. The Vince Lombardi Cancer Hotline provides a link to the
Wisconsin community. The Hotline receives calls from health professionals,
patients, family members and interested consumers, requesting information
about the latest approaches and research for treatment of specific cancers.
In 1 993, three new research studies were funded:
.

Management of diarrhea due to acute radiation bowel reaction

.

Inherited pattern of dihydropyrimidine dehydrogenase deficiency

.

A randomized study of Duoderm Hydrocolloid dressings vs. Nugel
hydrogel dressings in the management of radiation skin reactions

The Vince Lombardi Cancer Clinic is committed to making cancer a
preventable and controllable disease. The clinic strives to bring Southeastern
Wisconsin the best cancer care possible.
Marija Bjegovich, RN
Vince Lombardi Cancer Clinic
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AUTOLOGOUS BONE MARROW REINFUSION
FOR BREAST CANCER
High dose chemotherapy with autologous bone marrow/peripheral stem cell
reinfusion has been available at St. Luke’s since 1991 as a therapeutic option
for some women with breast cancer. Since April 1 991 more than 65 women
have undergone this treatment here. This therapy can offer improvements
(over conventional chemotherapy/radiation therapy) in long term survival in
women with Stage III or high risk Stage II disease. A select group of women
with locally recurrent or metastatic disease (those with minimal tumor burden
and chemotherapy responsive tumors) may also benefit from this approach.

Robert Taylor,
MD

This treatment is based on high dose chemotherapy. The reinfusion of
autologous hematopoietic cells is carried out as a rescue from the marrow
toxic side effects of the chemotherapy. The chemotherapy and reinfusion are
done on an inpatient basis, with a 21 day average length of stay. For most
patients, radiation therapy is given to the area of original disease on an
outpatient basis beginning 40-50 days post reinfusion. This is d’one in order
to help prevent local recurrence.
While this therapy offers hope for many women with aggressive breast cancer,
it is not without risks and side effects. Most patients will experience nausea,
vomiting, diarrhea and other chemotherapy related side effects. Patients are at
risk for infection and bleeding during the period of myelosuppression
following the treatment. Disease recurrence, in spite of aggressive therapy, is
also possible. Future work in the Autologous Bone Marrow Transplant
Program will focus on ways to further reduce treatment related toxicity and
decrease the incidence of recurrence following high dose chemotherapy/stem
cell reinfusion.

Robert Taylor, MD
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LUKE’S MEDICAL CENTER ABMI PROGRAM

The first Autologous Eone Marrow Transplant patient was “transplanted” at
St. Luke’s Medical Center on April 5, 1990. As ofJune of 1994, 108 patients
have undergone treatment for the following diseases:

1990

1991

1992

1993

1994

TOTAL

Non-Hodgkin’s Lymphoma

4

2

10

4

2

22

Hodgkin’s Disease

S

1

2

0

2

10

Multiple Myeloma

0

0

2

1

2

5

Other (Sarcoma, Glioma,

0

1

2

1

1

5

Breast Cancer, Adjuvant

0

1

14

10

5

30

Breast Cancer, Advanced

0

8

10

14

4

36

9

13

40

30

16

108

Ovarian cancer)

TOTAL

A

All statistics are non-actuarial. Patients less than 3 months post ABMT are
not included in the analysis below.
Non-Hodgkin’s Lymphoma (N = 21)
Disease Free Survival: 12 pts (57%)
Survival: 13 pts (62%)
Median Disease Free Survival: 19.5 mths
Median Survival: 19 mths
Disease Free Survival Range: 4-50 mths
Survival Range: 4-50 mths
Hodgkin’s Disease (N = 10)
Survival: 7 pts (70%)
Median Survival: 2$ mths
Survival Range: 4-46 mths

Disease Free Survival: 7 pts (70%)
Median Disease Free Survival: 2$ mths
Disease Free Survival Range: 4-46 mths

Multiple Myeloma (N = 3)
Survival: 2 pts (66%)
Median Survival 14 mths

Disease Free Survival: 1 Pt (33%)
Median Disease Free Survival: 14 mths

Breast Cancer, Adjuvant (N = 2$)
Disease Free Survival: 23 pts (82%)
Survival: 26 pts (92%)
Median Disease Free Survival: 16 mths
Median Survival: 17 mths
Disease Free Survival Range: 3-31 mths
Survival Range: 3-31 months
Breast Cancer, Advanced (N = 36)
Disease Free Survival: 10 pts (27%)
Survival: 14 pts (38%)
Median Survival: 9.5 mths
Median Disease Free Survival: 6 mths
Disease Free Survival Range: 3-32 mths
Survival Range: 3-32 mths

For more information regarding the ABMT program at St. Luke’s Medical
Center, please call 649-6472 or 649-6540.
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ThE CANCER PROGRAM TEAM

Marija Bjegovich,
RN

The Cancer Program team is a dynamic representation of many disciplines
from multiple departments and programs, such as: administration, inpatient
and outpatient nursing, clinical nurse specialists, social services, women’s
health, pharmacy, dietary, ministry, autologous marrow transplant,
immunotherapy and cancer outreach. This comprehensive team addresses all
areas of cancer care from prevention and early diagnosis to the ongoing
support and treatment follow-up for patients and families. Monitoring and
care for survivors and program development is also addressed.
A major effort was initiated toward community outreach. Far too many
people were developing cancers which were preventable. These concerns are
being addressed with a focus on community education by the Cancer
Outreach Coordinator through direct support from Vince Lombardi
Memorial Classic Funding. A community based lecture series, education &
screenings, and a physician-directed newsletter, are all part of the
coordinator’s activities. These activities are supported by the time and
expertise of the Cancer Program team. Team members not only address
issues with both patients and loved ones to promote total well being of the
family, they work with consumers and community based organizations to
help facilitate the goal of making cancer a curable or controllable disease.
Marija Bjegovich, RN
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FORMER PRESIDENT GERAlD FORD’S DAUGHTER FEATURED
AT BREAST CANGER AWARENESS PROGRAM
In recognition of Breast Cancer Awareness Month in October 1993,
St. Luke’s Medical Center Cancer Program presented a free public education
program featuring Susan Ford Bales, the daughter of former President Gerald
Ford and Mrs. Betty Ford.
Susan, a national spokesperson for breast cancer awareness for the past nine
years, is recognized as one of the most visible advocates for breast cancer
awareness. In her moving presentation, she shared her story as the daughter
of a woman with breast cancer, emphasizing the importance of early detection
and proper treatment. Marcia J.S. Richards, M.D., Medical Director of
Radiation Oncology at St. Luke’s, also spoke on the latest advancements in
breast cancer treatment and research.
The event drew an audience of 300 women and men to the Italian
Community Center. In addition to the educational presentations, St. Luke’s
cancer care specialists were available at educational booths to provide
information about breast cancer prevention, detection, screening
and treatment.
Earlier in the day, Susan discussed her story with reporters and representatives
from the Lombardi Foundation. The program was made possible through
support from the Vince Lombardi Memorial Classic.

Mary Fields
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SUPPORT... A TIME FOR SHARiNG
For people whose lives have been touched by cancer, support groups provide
education, a sharing of experiences, and inspiration. St. Luke’s Medical
Center offers support groups that meet the needs of a variety of individuals.

Keriy Twite, RN,
MSN, OCN

Support groups offer people a time to gather together for hope, information,
education and friendship. For one of the women in the ovarian cancer awareness group, “The support group has given me the chance to make changes in
my life and learn to deal with this illness during my recovery. It has given me
the opportunity to meet other women who have gone through treatment and
see their courage and give me hope. I also have new friendships who I see as
an inspiration to me and have a greater appreciation of my friends.”
“Make Today Count”, brings together people with cancer or other lifethreatening illnesses so they can help each other learn to live in a positive,
meaningful manner. For the men and women that nake today count, each
day is a gift to be enjoyed as fully as possible.
For the child who must cope when a parent has cancer, the “Kids
Connection” provides an avenue for kids to express their fears and concerns
in a nurturing environment. Innovative interventions and creative activities
are used to facilitate expression of feeling.

Jeannette Wade,
RN, BSN

Connection to others is a cornerstone for support groups. “Your Caring
Connection” enables persons diagnosed with cancer, family members, and
friends to discuss their experience of living with cancer. Through sharing their
stories, people discover similarities in their experiences and learn from others
how to cope and enjoy life.
The newest support group brings together the men and women who have
undergone an Autologous Bone Marrow Transplant. This support group
meets monthly on the first Thursday of the month from 6:30 pm to 8:00 pm
in the Vince Lombardi Cancer Clinic. One patient, when asked why he came,
said “I know it’s hard but you can do it. I came to help the next person get
through it. Among members of the support group, encouragement and hope
are shared.
“

Kerry Twite, RN, MSN, OCN
Jeannette Wade, RN, BSN
Mary Schmidt, RN, MS, OCN
Mary Schmidt,
RN, MS. OCN
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SUPPORT GROUPS OFFERED Al
St LUKE’S MEDICAL CENTER
Many ongoing supportgroups are offered by St. Luke’s Medical Center to the
surrounding community. The support groups available cater to a wide variety
of needs. Here are the groups offered for cancer support and grief support:

Cancer Support
“Kids Connection,”A support group to help children, ages 5 through 15, cope
when a parent has cancer. FREE. Registration is required. Call the Vince
Lombardi Cancer Hotline at 649-7200, for specific times and dates.
“Make Today Count,”A support group for families and persons with cancer
or other life-threatening illnesses, sponsored by St. Luke’s Medical Center, it is
held the fourth Thursday of each month from 7:30-9 p.m. at Cudahy United
Methodist Church, 5865 5. Lake Dr. FREE. Call the Vince Lombardi Cancer
Hotline at 649-7200.

A

“Your Caring Connection,” A support group for patients experiencing cancer,
their families and friends, is held at the Vince Lombardi Cancer Clinic, at
St. Luke’s Medical Center, on the second and fourth Monday of each month,
from 6:30-8 p.m. FREE. Call the Vince Lombardi Cancer Hotline
at 649-7200.
“Ovarian Cancer Awareness Group,” A support group for women with
ovarian cancer, their families and women who feel at risk for ovarian cancer,
is held at St. Luke’s Medical Center, the first Tuesday of each month from
6:30-8 p.m. FREE. Call the Vince Lombardi Cancer Hotline at 649-7200.
“Bone Marrow Support Group,” meets on the first Thursday of each
month from 6:30-8 p.m. at the Vince Lombardi Cancer Clinic. For more
information, call the Vince Lombardi Cancer Hotline at 649-7200.

Grief Support Groups:
“Loss of Parent for Adults,” support group meets Thursdays for six
weeks, from 6:30-8:30 p.m., is held at St. Luke’s Medical Center. A $10
donation is suggested, but may be waived. For more information,
call 649-7315.

“Loss of a Parent for Children,” call St. Luke’s Medical Center at 649-7315
for specific dates and times.
“Recently Widowed,” A support group meets on Tuesdays from 1-3 or
7-9 p.m. at St. Luke’s Medical Center. A $10 donation is suggested, but may
be waived. For more information, call 649-7315.
“Survivors Helping Survivors,” A self-help group for persons mourning the
death of a loved one by suicide, is held the second Tuesday of each month
from 7-9 p.m. at St. Luke’s Medical Center. FREE. For more information,
call 649-6230.

For more information on these and other support groups available at
St. Luke’s medical center, please call 649-7114.
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1993 CANCER ANNUAL REPORT STATISTICS
Cancer Registry Report
In 1993, the Cancer Registry at St. Luke’s Medical Center accessioned 1,483
new cases: 1,330 analytic and 153 non-analytic. Of these new cases, 59%
(875) of the patients were first diagnosed here and 30% were diagnosed elsewhere but recieved their first course of treatment here. The five most com
mon cancer sites in 1993 were breast, skin, lung, prostate, and colon which is
consistent with Wisconsin predictions. According to the American Cancer
Society’s Cancer Facts & Figures 1 993, the most common estimated sites for
Wisconsin in 1993, (not including Basal Cell Carcinoma or Squamous Cell
Carcinoma of the skin) were to be prostate, breast, colon/rectum, and lung.
At St. Luke’s, females accounted for slightly over half of the new cases
(50.8%) with males accounting for 49.2%. A majority of the patients (1,122
or 76%) were between the ages of 55 and 84. Malignancy was confirmed by
tissue confirmation in over 97% of the cases. Adenocarcinoma was the most
frequent histology followed by Infiltrating Duct Cell Carcinoma, Squamous
Cell and Basal Cell Carcinomas.
The Cancer Registy data base now includes information on over 22,000 cancer patients, approximately 5,000 of which are being followed on an annual
basis. With the assistance of physicians, office staff, area hospitals and fellow
Cancer Registrars, we have maintained a 98 % follow-up rate. The remaining
2%, our lost to follow-up patients, are well within the 10% allowed by the
American College of Surgeons.
The registry supplies data to physicians, administrative staff, and others for
research, surveys, and marketing. We have participated in various studies and
audits and always appreciate the opportunity to supply needed data to
requestors. The graphs and charts throughout this 1993 Cancer Program
Report can only present a brief overview of cancer diagnosis and treatment at
St. Luke’s Medical Center. Comparisons to State and National data, with
narratives, have been done when available. For further information, please
direct requests to the Cancer Registry Staff at 649-6720.
Sandy Blixt, RRA
Cancer Registry Coordinator

According to Cancer Facts & Figures 1 993: The following is a comparison
ofnational and state estimates for cancer diagnosis and St. Luke’s Medical
Center (SLMC) 1 993 actual figures. It reveals a higher than estimated
number ofbreast cancer cases but a lower than expected distribution of
prostate and colorectal cancer here at St. Luke’s.
-

SITES
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1993 U.S.A.

1993 WISCONSIN

(Estimated no. ofcases)

1993 SLMC

(Estimated no. ofcases(

(Actual no. of cases(

Breast

182,000 (15.6%)

3,600 (15.7%)

246(16.6%)

Lung

170,000(14.5%)

2,800(12.2%)

210(14.2%)

Prostate

165,000(14%)

3,800(16.5%)

147(10%)

Colorectal

152,000 (13%)

3,200 (13.5%)

150 (10.1%)

-

-

-

1993 CANCER ANNUAL REPORT STATISTICS

SITE

1993 Site Distribution

124$

Breast
Skin
Lung
Prostate
Colon
Bladder
Rectum, Rectosigmoid Junction
Lymph Nodes
Unknown and ill-Defined Sites
Kidney, Renal Pelvis
Hematopoietic System
Endometrium
Pancreas
Brain, CNS
Lip, Oral Cavity, Pharynx
Ovary
Cervix
Stomach & ill-Defined Digestive Organs

)
1
7

c_

I

z

Larynx

Liver, Gallbladder, Bile Ducts
Male Genitalia
Thyroid
Esophagus
Soft Tissue
Thymus, Heart, Mediastinum
Female Genitalia
Bone
Eye & Lacrimal Gland
Small Intestine
Trachea
Accessory Sinuses
Peritoneum 1

0

I
7
7

40

80

160
120
Number of Cases

240

200

280

Class Of Case At Diagnosis

Number Of Cases

9

Class Of Case

875

Class 1 -First Diagnosed And All Or Part
Of First Course Of Therapy Done At
This Facility

446

Class 2 -First Diagnosed Elsewhere And
All Or Part Of First Course Of Therapy
Done At This Facility

151

Class 3 -First Diagnosed And All Of First
Course Of Therapy Elsewhere,
Subsequent Courses Of Therapy At
This Facility

2

Class S -First Diagnosed At Autopsy, An
Incidental Finding Of Cancer At Time
Autopsy Performed

1483

Class 3

Class 0 -First Diagnosed At This Facility
And All First Course Of Therapy
Elsewhere

-

Class 2
[30.1%)

(59%)
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Total number of Patients Accessioned: 1,483

1993 New Case Distribution By Age

Female: 754

0-4
5-9
10 14

0

15

0

-

-

19

Male:

729

(50.8%)
(49.2%)

20 -24
25 29
-

.

0

DIAGNOSTIC CONFIRMATION

30-34

tz
40-44

55

45-49
Ii

60 64
-

65 69

127

-

-

Number of
Cases/Percent

POSITIVE HISTOLOGY
( specimens from biopsy, -‘
frozen section,surgery, autopsy,
orD&C)

1386 (93.5%)

4

50-54
55-59

70

Type of
Confirmation

74

‘-‘.J

75 79

9

-

80 84
-

85+

0

40

80

120

160

240

200

280

Number of Cases

15 Most Frequent Histologies

-

1993

Hito1ogy
Adenocarcinoma

POSITIVE MICROSCOPIC
( cases microscopically confirmed
but without details on the method)
LABORATORY TEST!
MARKER STUDY
(based on lab tests or marker studies
clinically diagnostic for cancer)

10

Infiltrating Duct Cell Carcinoma
Squamous Cell Carcinoma

POSITIVE CYTOLOGY
(microscopic examination of cells;
sputum smears, bronchial brushings,
washings, secretions, and fluids)

40

Basal Cell Carcinoma
Carcinoma

53 (3.6%)

1 (.1%)

2 (.1%)

Small Cell Carcinoma
Large Cell Carcinoma

VISUAL CONFIRMATION
( surgical exploration or use of scopes
when visualization not supplemented
by positive histology or cytology)

)

Malignant Melanoma
Papillary Transitional Cell Carcinoma

127

Transitional Cell Carcinoma

I 26

Malignant Lymphoma

6 (.4%)

Lobular Carcinoma
Papillary Adenocarcinoma
Malignant Lymphoma, Large Cell, L_
Ineraductal Carcinoma, Non-infiltrating
All others (105 with counts not displayed)

0

50

100

150

200

250

300

350

400

450

RADIOGRAPHIC
( based on imaging techniques for
cases where there is no positive
histology or cytology)

18 (1.2%)

CLINICAL DIAGNOSIS
(clinical methods not mentioned
previouslyfor cases where there
is no positivehistology or cytology)

13 ( .9%)

Number of Cases

Over 97% ofall SLMC cancer cases in 1 993 were microscopically
diagnosed. This helped determine the cell type and other
characteristics of the tumor which is used in treatment planning
and sometimes to identify the primary site or the extent of tumor
spread. Cancers not diagnosed microscopically tended to be cases
for which surgery was not performed or for which further
work-up was not provided due to the patient’s refusal or death,
or on the advise ofthe physician.
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UNKNOWN
(No information available as to
whether or not microscopically
confirmed)

4 (.3%)

1993 CANCER ANNUAl REPORT STATISTICS
SLMC
All Sites

General Summary Stage at Diagnosis
‘1993 SLMC

1992 WI

Local

53.6%

43%

Regional

20.4%

23%

Distant

16.9%

15%

-

1993

—_-—-—4.2% In situ
4.9% Unkown

E6.9% Distant
20.4%—”
Regional

For most types of cancer, the extent of tumor spread at the time of initial diagnosis contributes to prognosis. Treatment
of cancers diagnosed before spread is more often treated by surgery or by radiotherapy of a small area, while cancers that
have spread require more systemic treatment. The charts reveal that in 1993, 4.2% of our patients were diagnosed with
in situ disease and 53.6% were diagnosed with local disease. Almost 17% of our patients were diagnosed with distant
disease. A comparison is made between 1993 SLMC (St. Luke’s Medical Center) data, 1992 state of Wisconsin data
(most current figures available) and 1983-87 SEER Program data. A comparison of stage at diagnosis for skin cancer is
not available since the Wisconsin Cancer Reporting System and SEER exclude non-melanomas of the skin from their
published totals and we include them. St. Luke’s has a larger percentage of lung, colon, and prostate cancer patients
diagnosed with local disease than both Wisconsin and SEER. Other figures vary with our facility averaging between those
of Wisconsin and SEER in many cases.

1993 General Summary
Stage for iop 5 Sites

Breast (248 patients)

Local
Regional
Distant

‘p1993 SLMC

1992W1

1983-87 SEER

54%

57%

53%

28.2%

26%

37%

6.5%

A 0/
-t /0

I /0

9.7%
c_______In situ
1.6%
L65%
Unkown
Distant
—

28.2%
Regional

*

Percentages do not equal 100% due to exclusion ofln situ and
Unkown Stages.
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Skin (216 patients)

Distant

Percent

In situ

10

4.6%

Local

201

93.1%

2

.9%

1’

.5%

2

.9%

Regional

4.6%
93.1 %4
Local

SLMC

0.9%
Unknown
Unkown
Regional

216
Stage at diagnosis comparisons for skin carcinomas are
not available for state and national figures. These
figures include Basal Cell Carcinomas and Squamous
Cell Carcinomas in addition to Melanomas and other
skin cancers.

Lung (210 patients)

25.3 %—i
Regional

3.8%
Unkown

T__ 31.9% Distant
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‘1993SLMC

1992W!

19$3-87SEER

Local

39%

22%

16%

Regional

25%

30%

32%

31.9%

38%

37%

Distant

1993 CANCER ANNUAL REPORT STATISTICS

Prostate ( 147 patients)
‘p1993 SLMC

1992W1

1983-$7SEER

Local

74.8%

69%

58%

Regional

10.2%

15%

14%

Distant

10.2%

7%

18%

74.8%
Local
A

4.$%Unkown
10.2% Distant
S

10.2% Regional

Colon (103 patients)

Local
Regional
Distant

‘1993 SLMC

1992W1

1983-87SEER

36.9%

33%

34%

33%

41%

40%

18.4%

16%

20%

33 %
Regional

Unkown
18.4% Distant
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SI. LUKE’S CANCER CONFERENCES
TUMOR BOARD CONFERENCE:
Conferences were held on the first, second and fourth Mondays of every
month at noon. A new format began in 1993 with a physician and
pathologist, working together as co-moderators, identifying potential cases for
presentation and discussion at Tumor Conference. Moderators included
representatives from Radiation Oncology, Medical Oncology, Surgery,
Urology, and Pathology. This patient oriented, multi-disciplinary conference
has the advantage of a moderating pathologist who identifies and provides
“newly diagnosed” andlor uncommon cancers cases immediately. The second
moderator, a specialist, may select his/her own current cases or choose those
of other physicians. The cases are then given to the Cancer Registry who
contacts Laboratory Medicine, Radiology, Nuclear Medicine and other
departments to request the slides and films necessary for case presentation. A
summary of the patient’s work-up and treatment todate is then typed for
distribution at the conference. All physicians involved in the cases are invited
to attend. The conferences provide a setting for interdisciplinary discussion of
treatment options and at the same time a teaching experience for residents,
medical students and hospital employees. The conferences have an average
attendance of 40. For more information regarding the Tumor Conference, or
to make arrangements to have a case presented, please call 649-6720.

Tumor Conference Review of Cancer Sites
-

No. of Cases
Site
Lung
15
ColonfRectum
12
Breast
10
BrainJCNS
8
Hodgkin’s Disease
5
Bladder
5
Stomach
5
Endometrium
S
Unknown
4
Thyroid
4
Lymphoma
4
Prostate
3
Kidney
3
Testis
3

Small Intestine
Pancreas
Appendix
Liver
Pituitary
Ovary
Histiocytoma
Esophagus
Leukemia
Melanoma
Sarcoma
Thymoma
Kaposi’s Sarcoma

No. of Cases
2
2
2
2
2
2
2
2
1
1
1
1
1

HEAD AND NECK TUMOR CONFERENCE:
Conferences were held on the third Monday of every month at noon. They
were held to discuss selected difficult head and neck tumors from a multidisciplinary approach. Some of the sites discussed include the sphenoid,
ethmoid, maxillary sinus, tongue, larynx, piriform sinus, nasal sidewalls,
trachea, and lymphomas. For more information regarding the Head and
Neck Tumor Conference, please call 649-3900.
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St LUKE’S CANCER CONFERENCES
June 7, 1993

The Role of Mammography
Edward A. Sickles, M.D.
Professor of Radiology
University of California San Francisco
-

Sponsored by the Schroeder Fellov Program in
Clinical Oncology
September 18, 1993

The First Annual St. Luke’s Schroeder Cancer
Conference For Physicians
Sponsored by the Schroeder Fellows Program in
Clinical Oncology
“The Management of Esophageal Cancer”
David J. Sugarbaker, M.D.
Associate Professor of Surgery
Chief, Division of Thoracic Surgery
Lung Transplant Program
Harvard Medical School
Brigham and Women’s Hospital
Boston, MA
“PSA and Prostate Cancer: What Physicians
Need To Know”
Joseph E. Oesterling, M.D.
Associate Professor of Urology
Mayo Clinic
Rochester, MN
Editor-in-Chief, Urology
“Hereditary Cancer and Cancer Genetics”
Robert R. Lebel, M.D.
Genetic Services
Elmhurst, IL
“The Management of Minimally Invasive
Breast Cancer”
Richard G. Margolese, M.D., FRCS (C)
McGill University
Director of Clinical Oncology
McGill Comprehensive Cancer Center
Director, Department of Oncology
Sir Mortimer B. Davis Jewish General Hospital
Montreal (Quebec), Canada

September 29, 1993

High Dose Chemotherapy in Primary and Metastatic
Breast Cancer
William Peters, M.D.

October 7, 1993

The Immunotherapy of Solid Tumors
D. Schwartzentruber, M.D.
Security Bank Lecture
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I anuary 21, 1993

“Cancer Prevention and Early Detection”
Paul P. Hartlaub, MD, Assistant Professor,
Family Medicine & Practice
Sharon Thompson, Registered Dietitian
Becky Pogacor, RN, Pulmonary Medicine
Kerry A. Twite, RN, Clinical Nurse Specialist

March 1, 1993

“Prostate Cancer What You Need to Know”
Stuart Fine, MD, Urologist

May 20, 1993

“Survivorship: Living With, Through, and
Beyond Cancer”
Susan Leigh, RN, President of the National
Coalition for Cancer Survivorship

July 22, 1993

“Skin Cancer: Advancements in Treatment
Overview of Skin Cancer, Radiation Therapy &
Skin Cancer, Immunotherapy and Melanoma”
Thomas J. Russell, MD
J ames E. Bruckman, MD
J ohn P. Hanson, MD

-

GLOSSARY
Adjuvant Chemotherapy: One or more anti-cancer drugs used in combination with (in addition to) surgery or radiation therapy
as a part of cancer treatment.
Analytic Cases: Cases which are first diagnosed and/or given their first course of treatment at St. Luke’s Medical Center.
Biopsy: A procedure where a piece of tissue or fluid (a group of cells) is taken from a person’s body and examined with a
microscope to see if the cells are normal or not.
Bone Marrow: The soft, spongy center of the bone, the “factory” that produces blood.
BRM: (Biological Response Modifier) Any agent that boosts the body’s immune system by stimulating it, modifying it or
restoring it.
Chemotherapy: Treatment with powerful drugs that attack cancer cells.
Clinical Trials: Studies designed to evaluate promising new treatments by helping researchers learn which approaches are more
effective than others.
Combined Therapy: Refers to any combination of surgery, radiation, chemotherapy, hormone therapy or other therapy
administered jointly as a single course of treatment
Diagnostic Only: Cancer related treatment was not given due to the patient refusing treatment or his/her general condition being
unsatisfactory for treatment.
Diethyistilbestrol: (DES) A synthetic estrogenic compound prescribed in the past to prevent spontaneous abortion.
Distant Stage: A neoplasm that has spread to other organs or lymph nodes from the primary tumor.
First Course Treatment: The tumor directed treatments started within the first four months after diagnosis
Immunotherapy: Use of the immune system or the products of the immune system to control, damage, or destroy malignant
cells.
In situ: A tumor classified microscopically as in situ, non-invasive, pre-invasive, non-infiltrating, intraductal, intraepithelial or
intraepidermal
Local Stage: Tumor restricted to the organ of origin, but may be invasive or infiltrating within the organ of origin
Lump: A thickness under the skin that can be felt by the fingers, either by the person who has it or by a doctor. A lump can be a
sign of cancer, but most lumps are not cancerous.
Lumpectomy: Surgical removal of the cancerous portion of the breast and a small amount of surrounding tissue.
Lymph: A nearly clear fluid collected from tissues around the body and returned to the blood via the lymphatic system
Lymphedema: Unilateral or bilateral edema of the extremities due to accumulation of interstitial fluid as a result of stasis of
lymph, which is secondary to obstruction of lymph vessels or disorders of the lymph nodes.
Lymph Nodes: Small bean-shaped structures scattered along the vessels of the lymphatic system. The nodes filter bacteria and
cancer cells that may travel through the system.
Mammography: A low-dose X-ray of the breast that can detect cancer in the early stages.
Metastasis: The spread of cancer from its original site to distant areas. The cancer cells are carried to distant sites by blood and
lymph.
Non-Analytical: Cases which are seen at St. Luke’s Medical Center after the first Course of treatment.
Palliative Treatment: The use of medical remidies to relieve pain, symptoms, and/or prevent further complications rather
than to cure.
Partial Mastectomy: Surgical removal of up to one quarter of the breast tissue and all or some of the lymph nodes in the armpit.
Prognostic Indicators: A symptom or sign on which a prognosis may be based.
Prone Position: Lying face downward.
Radiation Therapy: Treatment with high-energy radiation from x-rays or other sources of radiation that damages or kills cells.
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GLOSSARY
Radical Mastectomy: The removal of the breast and skin, the underlying muscle of the chest wall, the axillary lymph nodes, and
fat tissue.
Regional Stage: A tumor that has extended beyond the limits of the organ of origin into 1) surrounding organs or tissues by
direct extension, 2) regional lymph nodes by metastasis, or 3) a combination of 1 and 2 and appears to have spread no further.
Recurrence: The return of cancer after a disease-free interval.
Regression: Growing smaller or disappearing. Used to describe shrinkage or disappearance of a cancer.
Risk Factors: Factors such as age, early onset of menstruation, late menopause, and family history of breast cancer that may
increase the risk of breast cancer.
Stage: A term used to describe the size and extent of spread of the cancer.
TRAM Flap: (Transverse Rectus Abdominus Musculocutaneous Flap) Uses tissue from the lower abd@minal wall overlying the
rectus abdominus muscle area. The tissue from this area is often sufficient to create a breast shape
satisfactory enough not to require an internal implant.
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